Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22
CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory
B-lineage acute lymphoblastic leukemia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology